Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Using inhaled antibiotics to treat lower respiratory tract infections could help reduce antimicrobial resistance, according to researchers from the University of Bristol and University of Bath.

Acute lower respiratory tract infections (aLRTIs) are the most common condition managed in primary care worldwide and antibiotic resistant strains are the leading cause of antimicrobial deaths. Oral antibiotics are currently inappropriately given in around 50% of cases, contributing to antimicrobial resistance and medicines waste.

In an article published in The Lancet Respiratory Medicine [11 May], the researchers propose that inhaled antibiotics could be effective in treating people seen in primary care, particularly those with long term lung conditions such as asthma and COPD (chronic obstructive pulmonary disease). These patients are already familiar with using inhalers, and inhaled antibiotics could deliver higher concentrations in smaller doses than when taken by mouth, and therefore cause less harm.

Professor Alastair Hay from the Centre for Academic Primary Care, University of Bristol and lead author of the article said: “The evidence base for using inhaled antibiotics is really lacking, but the evidence that is available suggests that they could be a game-changer when it comes to the treatment of aLRTIs. It’s vital that we consider all possible avenues to reduce antimicrobial resistance, which remains a major threat to public health globally.

“A lot of damage can be done through the inappropriate use of oral antibiotics, including side effects such as diarrhoea, vomiting and skin rashes, and damage to healthy gut bacteria that are indiscriminately destroyed, allowing resistant bacteria to flourish. Inhaled antibiotics could reduce side effects and these so-called ‘bystander’ antimicrobial resistance effects, by ensuring only the affected part of the body is treated.

"We are calling on Governments around the world to make funds available for companies to develop new drug delivery systems so that patients can reduce their use of oral antibiotics and thereby reduce the risks of developing side effects and acquiring antibiotic resistant bacteria.”

Comment article: Inhaled antibiotics for acute lower respiratory tract infections in primary care: a hypothesis by Alastair Hay, Albert Bolhuis, Alyson Huntley and Matthew Jones. The Lancet Respiratory Medicine. May 2022.

Published with thanks to University of Bristol, Centre from Academic Primary Care